Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene

Citation
H. Kokado et al., Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene, CIRCULATION, 102(6), 2000, pp. 663-669
Citations number
40
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CIRCULATION
ISSN journal
00097322 → ACNP
Volume
102
Issue
6
Year of publication
2000
Pages
663 - 669
Database
ISI
SICI code
0009-7322(20000808)102:6<663:CFOHCC>2.0.ZU;2-I
Abstract
Background-Mutations that cause hypertrophic cardiomyopathy (HCM) have been identified in 9 genes that code proteins in the sarcomere, Previous report s have demonstrated that cardiac troponin I (cTnI) gene mutations may accou nt for familial HCM; however, the clinical characteristics and prognosis of patients with HCM caused by cTnI gene mutations are not known. Methods and Results-We analyzed cTnI gene mutations in 130 unrelated proban ds with HCM and their families to clarify the genotype-phenotype correlatio ns. We identified 25 individuals in 7 families with a Lys183 deletion (Lys1 83 del) mutation in exon 7 of the cTnI gene. The disease penetrance in subj ects aged >20 years was 88% by echocardiography and 96% by EGG. Sudden deat h occurred in 7 individuals of 4 families at any age. Overall, 7 (43.8%) of 16 individuals aged >40 years had left ventricular systolic dysfunction, a nd 3 (18.8%) displayed dilated cardiomyopathy-like features. Of affected in dividuals, 4 of 5 individuals aged >40 years followed by echocardiography s howed septal thinning and decreased fractional shortening during >5 years o f follow-up. Conclusions-The Lys 183 del mutation in the cTnI gene in patients with HCM is associated with variable clinical features and outcomes. HCM caused by t he Lys 183 del mutation has a significant disease penetrance. This mutation is associated with sudden death at any age and dilated cardiomyopathy-like features in those aged >40 years. However, it remains unclear whether scre ening of families with HCM for this mutation will be useful in patient mana gement and counseling.